RxSight, Inc. (NASDAQ:RXST) Director Jesse Anderson Corley Purchases 11,111 Shares

RxSight, Inc. (NASDAQ:RXST) Director Jesse Anderson Corley purchased 11,111 shares of the firm’s stock in a transaction dated Tuesday, November 12th. The shares were acquired at an average cost of $45.37 per share, with a total value of $504,106.07. Following the completion of the purchase, the director now directly owns 468,571 shares in the company, valued at approximately $21,259,066.27. This represents a 2.43 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

RxSight Stock Performance

NASDAQ:RXST opened at $45.05 on Friday. RxSight, Inc. has a 12-month low of $27.07 and a 12-month high of $66.54. The stock’s 50 day moving average price is $50.32 and its two-hundred day moving average price is $53.28.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on RXST. Jefferies Financial Group began coverage on shares of RxSight in a research report on Tuesday, October 29th. They issued a “buy” rating and a $72.00 target price for the company. Wells Fargo & Company lowered their target price on RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Stifel Nicolaus dropped their target price on RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Needham & Company LLC restated a “buy” rating and issued a $66.00 price target on shares of RxSight in a research note on Friday, September 13th. Finally, Oppenheimer dropped their price objective on RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 6th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, RxSight presently has an average rating of “Buy” and an average price target of $61.63.

Institutional Investors Weigh In On RxSight

A number of large investors have recently added to or reduced their stakes in the business. Oppenheimer & Co. Inc. bought a new position in RxSight during the first quarter worth $364,000. Swiss National Bank lifted its stake in shares of RxSight by 16.2% during the 1st quarter. Swiss National Bank now owns 53,100 shares of the company’s stock worth $2,739,000 after buying an additional 7,400 shares during the last quarter. ProShare Advisors LLC bought a new stake in shares of RxSight during the 1st quarter worth about $263,000. Entropy Technologies LP grew its stake in RxSight by 67.2% in the 1st quarter. Entropy Technologies LP now owns 13,437 shares of the company’s stock valued at $693,000 after buying an additional 5,399 shares during the last quarter. Finally, M&G Plc acquired a new position in RxSight in the 1st quarter valued at about $7,354,000. Institutional investors own 78.78% of the company’s stock.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.